5-HT4 Inhibitors
1 drugsAbout 5-HT4
The 5-HT4 receptor, or serotonin receptor 4, is a serotonin receptor family protein that regulates various physiological processes as a receptor for serotonin. Its involvement in these processes makes it a compelling target for therapeutic intervention.
Currently, there is no genetic evidence data available linking the 5-HT4 receptor to specific diseases, warranting further research into its involvement in disease pathways.
The 5-HT4 receptor is targeted by one FDA-approved drug, MOTEGRITY (Takeda), a small molecule addressing an 'Other' therapeutic area.
Top 5-HT4 Drugs
Takeda is the only company with an approved drug targeting 5-HT4.
Low competition suggests easier market entry, but also indicates higher risk due to limited validation.
5-HT4 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 5-HT4, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for biologics or novel approaches.
5-HT4 Clinical Trials 27 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on 5-HT4. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 7 | 0 | 0 | 100% |
| Phase 2 | 3 | 3 | 0 | 0 | 100% |
| Phase 3 | 10 | 8 | 2 | 0 | 80% |
| Phase 4 | 7 | 5 | 1 | 1 | 83% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
5-HT4 Drug Approval Timeline (2018 - 2018)
The first and most recent drug approval for 5-HT4 was MOTEGRITY in 2018.
A single approval in 2018 suggests a potentially unsaturated market, but also limited clinical success.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 18 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on 5-HT4. A trial counts if an approved drug acting on 5-HT4 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.